Darbepoetin Alfa Not Advised for Anemic Heart Failure Patients

A recent study shows the popular medication didnt improve the health of heart failure patients whose conditions are complicated by anemia.

A drug that commonly prescribed to treat anemia in heart failure patients may not improve the patients health or reduce the risk of death from heart failure, according to a study presented at the American College of Cardiologys annual meeting in March. The study, conducted by researchers at the University of Gothenburg, Sweden, Cleveland Clinic and many other centers, found that patients who took the drug darbepoetin alfa experienced similar clinical outcomes as those who took a placebo. The study involved more than 2,000 anemic heart failure patients in 33 countries.
To continue reading this article or issue you must be a paid subscriber. Sign in

Subscribe to Heart Advisor

Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access